

PRODUCT INFORMATION



Irinotecan-d₁₀ (hydrochloride)

Item No. 22566

CAS Registry No.: 718612-62-5

Formal Name: (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate-2,2,3,3,4,4,5,5,6,6-d₁₀, monohydrochloride

Synonyms:

Camptothecin 11-d₁₀, CPT 11-d₁₀, Topotecin-d₁₀, U 101440E-d₁₀

MF:

C₃₃H₂₈D₁₀N₄O₆ • HCl

FW:

633.2

Chemical Purity:

≥95% Irinotecan (hydrochloride)

Deuterium

Incorporation:

≥99% deuterated forms (d₁-d₁₀); ≤1% d₀

Supplied as:


A solid

Storage:

-20°C

Stability:

≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Irinotecan-d₁₀ (hydrochloride) is intended for use as an internal standard for the quantification of irinotecan (Item No. 14180) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Irinotecan-d₁₀ (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the irinotecan-d₁₀ (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Irinotecan-d₁₀ (hydrochloride) is soluble in methanol and DMSO.

Description

Irinotecan, a derivative of the alkaloid camptothecin (Item No. 11694), functions as a prodrug that is converted by tissue carboxylesterase to 7-ethyl-10-hydroxycamptothecin, a potent inhibitor of DNA topoisomerase I.^{1,2} Its action is terminated by glucuronidation by UDP glucuronosyl transferase 1A1.^{3,4} Formulations containing irinotecan demonstrate broad spectrum antitumor activity against metastatic colorectal cancer, small cell lung cancer, and several other solid tumors and have proven useful in radiation treatment of tumors by sensitizing tissue to radiation damage.^{1,2}

References

1. Rothenberg, M.L. Topoisomerase I inhibitors: Review and update. *Annals of Oncology* **8**(9), 837-855 (1997).
2. Dancey, J., and Eisenhauer, E.A. Current perspectives on camptothecins in cancer treatment. *Br. J. Cancer* **74**(3), 327-338 (1996).
3. Mathijssen, R.H.J., van Alphen, R.J., Verweij, J., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). *Clin. Cancer Res.* **7**(8), 2182-2194 (2001).
4. Ma, M.K., and McLeod, H.L. Lessons learned from the irinotecan metabolic pathway. *Curr. Med. Chem.* **10**(1), 41-49 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM